Decision Tree Placement: Important to determine where a new test fits within the diagnosis hierarchy.
Differential Diagnoses: Many conditions, especially autoimmune diseases, may present similarly; distinguishing features are crucial.
Reference: Graus, Francesc et al. (2016). A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology, 15(4), 391-404.
Physician Judgment: Decisions based on symptoms due to the high costs and lengthy turnaround times of diagnostic tests.
Integrative Approach: A new test should define its role in relation to existing diagnostic methods.
Autoantibodies: Characterization of autoimmunity often involves measuring autoantibodies; research focuses on innovative identification techniques.
Asthma Example
Patient Compliance: Issues with test adherence particularly among children and elderly populations.
Misdiagnosis Risks: Subpopulations such as obese patients might not reflect typical disease severity.
Reference: Sackmann, Eric Karl-Heinz et al. (2014). Characterizing asthma from a drop of blood using neutrophil chemotaxis. Proceedings of the National Academy of Sciences, 111(16), 5813-5818.
Neutrophil Chemotaxis:
Purification of neutrophils
Application of chemokines for testing chemotactic ability (speed, index)
Automation of tracking analysis for efficient data collection
Comparison with Gold Standards: Important to establish optimal specificity/sensitivity cut-off for the biomarkers in use.
Microfluidics
Innovation in Diagnostics: Microfluidic systems improve reagent and sample efficiency, sensitivity, and integration of processes.
Example: Eamer, Lise et al. (2015). Microfluidic assessment in sperm selection. Biomicrofluidics, 9(4), 044113.
Challenges: Reliability of external components (e.g., syringe pumps), manufacturing complexities, and sample preparation requirements.
Advantages: Reduced processing time and resource consumption.
Allergy Example
Limitations of Current Tests:
Skin prick tests may not accurately predict reactions due to differences in immune system responses or unrelated skin conditions.
Serum IgE tests may not correlate with disease severity, especially post-immunotherapy.
Nanostructured Biosensors:
Recent innovations allow for miniaturization of assays requiring only small serum samples (25 μL).
Faster detection times (<1 minute) with improved multiplexing potential.
Challenges include scalability and robust correlation with traditional methods.
Microfluidics in Allergy Testing:
Simplified infrastructure requirement with rapid assay time and high throughput potential.